earnings
confidence high
sentiment negative
materiality 0.70
OptimizeRx Q2 revenue up 3% to $14M, GAAP net loss of $3.9M, cuts FY 2022 outlook
OptimizeRx Corp
2022-Q2 EPS reported
-$0.42
revenue$27,710,195
- GAAP net loss of $3.9M ($0.21/sh) vs prior-year net income of $0.4M ($0.02/sh).
- Non-GAAP net income of $0.7M ($0.04/sh) down from $1.8M ($0.10/sh) a year ago.
- Gross margin improved to 64% from 59%; revenue of $14.0M, +3% YoY.
- FY 2022 revenue guidance lowered to $62-68M (1-11% growth); gross margin 59-62%.
- Share repurchase program authorized up to $20M; 232,745 shares bought at avg $23.02.